In recent years, the incidence and mortality rates of head and neck squamous cell carcinoma (HNSCC) have increased worldwide. Therefore, understanding genomic alterations in HNSCC carcinogenesis is crucial for appropriate diagnosis and therapy. Protocadherin FAT1, which encodes 4588 amino acid residues, regulates complex mechanisms to promote oncogenesis or suppression of malignancies. Multiplex PCR-based next-generation sequencing (NGS) revealed FAT1 somatic mutations. The clinicopathologic implications of FAT1 in HNSCC were investigated using expression assays, and the functional role of FAT1 in HNSCC pathogenesis was determined using ectopic expression and knockdown experiments. Approximately 29% patients with HNSCC harbored damaging FAT1 mutations. InVEx algorithm identified FAT1 as a significant functional mutation burden. Each type of mutation (missense, nonsense and frameshift) accounted for nearly one-third of deleterious mutations. FAT1 mutations correlated with lower FAT1 expression in tumors. The knockdown of the endogenous expression of FAT1 and exogenous expression of crucial FAT1 domains unequivocally indicated that FAT1 suppressed the migration and invasion capability of HNSCC cells. Functional analysis suggested that nonsense mutations in FAT1 result in the loss of the suppression of tumor progression. FAT1 mutations and downregulation defined nodal involvement, lymphovascular permeation and tumor recurrence. In addition, FAT1 mutations and downregulation are independent predictors of poor disease-free survival in patients with HNSCC. This study is the first to perform multiplex PCR-based NGS to indicate marked non-synonymous FAT1 mutations in HNSCC, which are prognostic indicators. The gene analysis strategy proposed for detecting FAT1 mutations may be a valid method for mutation screening.
Introduction
Head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC), is the sixth most prevalent malignancy worldwide (1, 2) . Many molecular factors, including mutations in TP53, NOTCH family genes and PIK3CA-related elements, contribute to HNSCC pathogenesis; other factors are also under investigation (3, 4) . However, the role of these factors in tumor progression is largely unclear (5) (6) (7) . Despite advances in knowledge on head and neck carcinogenesis and innovations in surgery, chemotherapy and radiation therapy, the survival rates for many types of HNSCCs have not improved significantly in the past 40 years (8) . Recent whole-exome sequencing (WES) studies have provided advanced insight into the molecular model of HNSCC progression (9) (10) (11) . WES data obtained from The Cancer Genome Atlas (TCGA) (12, 13) further highlight this molecular complexity by identifying novel significantly mutated genes (14) . These studies have reported that HNSCC is characterized by a high degree of intertumor heterogeneity, further confirming the complexity of HNSCC pathogenesis.
The human atypical FAT1, a type 1 transmembrane protein, is a member of the FAT family, which is an ortholog of the Drosophila fat gene family. It is a large gene and encodes 4588 amino acid residues composed of 34 cadherin repeats, a lamin G-like motif, and 5 epidermal growth factor (EGF)-like repeats in the extracellular region, a transmembrane region and a cytoplasmic tail (15) . FAT1 undergoes proteolysis to release an intracellular domain, which can translocate into the nucleus (16) . The FAT1 intracellular domain interacts with β-catenin and prevents this translocation (17) . Moreover, it interacts with Ena/VASP and Scribble (18, 19) , promotes actin-modulated cell migration and inhibits YAP1-associated cell proliferation (18) . Thus, the role of FAT1 is highly debated, being reported as a tumor suppressor (4, (20) (21) (22) and promoter (23) . In addition, FAT1 has been reported to undergo aberrant processing in many human cancers, including melanoma, pancreatic cancer and HNSCC (17, 24, 25) ; this enhances its complexity in modulating carcinogenesis.
The mutation screening of a large gene with multiple exons through Sanger sequencing is feasible, but is very labor-intensive and costly. Hence, molecular techniques are frequently used as screening methods before finally confirming the variants through Sanger sequencing. The reduced cost of DNA sequencing offered by next-generation sequencing (NGS) has made it possible to forego the prescreening step and to directly analyze mutations for diagnosing monogenic diseases. However, novel variants identified through NGS should be further confirmed through Sanger sequencing before being reported. In this study, we performed multiplex PCR-based NGS to investigate FAT1 mutations in HNSCC. FAT1 mutations and expression were observed to affect HNSCC progression and survival. The inhibition and overexpression of FAT1 in cell lines showed the suppressive activity to tumor progression. Moreover, the functions of deleterious FAT1 mutations were investigated to determine their neoplastic roles in HNSCC.
Materials and methods

Patients
Tumor specimens were obtained from 101 patients with HNSCC during surgery (Supplementary Table 1 , available at Carcinogenesis Online). All patients provided written informed consent. This study was approved by the institutional review board of MacKay Memorial Hospital (approval numbers: 12MMHIS178 and 15MMHIS104). Laser capture microdissection was performed to retrieve cells from tissue sections according to previously established protocols (6, 7) . Before surgery, 10 ml of whole blood was collected from the patients (in the morning after fasting) in Vacutainer tubes containing ethylenediaminetetraacetic acid (Becton Dickinson, Franklin Lakes, NJ). None of the patients had received adjuvant chemotherapy or radiotherapy before surgery. Blood and cancer tissue DNA were extracted as reported previously (26) .
Whole-exome sequencing
Five paired samples of tumor tissue and blood cells from the patients were analyzed through WES. DNA from each sample was isolated using the SureSelectXT Reagent Kit (Agilent, Santa Clara, CA) and sequenced on a NextSeq500 sequencer by using the paired-end 100 bp protocol (Illumina, San Diego, CA). BWA (version 0.7.15, http://bio-bwa. sourceforge.net/) was used to align the sequencing data to the human reference genome (UCSC hg19, NCBI build 37) (27) . SAMtools (version 1.3.1, http://samtools. sourceforge.net/) was used for SAM-to-BAM conversion and to identify single-nucleotide variants (SNVs) and small insertions and deletions (indels) (28) . The variants were annotated using Ensembl Variant Effect Predictor (version 86, http://grch37.ensembl.org/index.html) (28) and were further filtered on the basis of the following criteria: (i) depth filtering <30; (ii) genotype quality <30; (iii) number of mismatches within a 40 bp window ≤3; (iv) a mutant allele frequency: at least 10% in tumors and <1% in normal cells and (v) minor allele frequency (MAF) in the 1000 Genomes Project and dbSNP137 > 1%. The potential functional effect of the missense mutations was predicted using SIFT (version 5.2.2, http://sift.jcvi. org/) and PolyPhen-2 (version 2.2.2, http://genetics.bwh.harvard.edu/ pph2/). The threshold for deleterious variants was as follows: SIFT ≤ 0.05 and PolyPhen-2 > 0.5. Genes harboring the loss of function as well as nonsense and frameshift variants were used for candidate gene prioritization. Finally, the candidate variants were visually confirmed using Integrative Genomics Viewer (IGV; version 2.3, http://software. broadinstitute.org/ software/igv/; Supplementary Figure 1 , available at Carcinogenesis Online) (29, 30) . Circos plots illustrating somatic mutations in HNSCC were generated using Circos-0.69 (http://circos.ca/software/) (31) .
Analysis of FAT1 mutations in HNSCC tissues through multiplex PCR-based NGS
Primer3 (version 0.4.0) was used to design all individual primer sets for the 10 long PCRs to amplify the entire coding sequence (exons 2-27) for FAT1 (Supplementary Table 2 and Figure 2A , available at Carcinogenesis Online). Long-PCR amplifications were performed using the KAPA LongRange HotStart Kit (Kapa Biosystems, Wilmington, MA). The concentration of each PCR amplicon was determined using the Qubit dsDNA HS Assay Kit on a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA). For library generation for each sample, long-PCR products were pooled and purified using Agencourt AMPure XP Beads (Beckman Coulter, Pasadena, CA). Indexed libraries of the pooled PCR products were prepared using the Illumina Nextera XT Library Preparation Kit, by following the protocol provided by Illumina, and were sequenced with the Illumina MiSeq system in accordance with the manufacturer's protocol. Variant call format files were generated using the MiSeq Reporter (version 2.3.32). The variants were further filtered based on the following criteria: (i) depth filtering <30; (ii) genotype quality <30; (iii) number of mismatches within a 40 bp window ≤3; (iv) mutant allele frequency: at least 10% in tumors and less than 1% in normal cells and (v) MAF in the 1000 Genomes Project and dbSNP137 > 1%. The IGV was used to determine the read counts of the target amplicons and confirm the detected variants. The mutation spectrum and lollipop figures for FAT1 were generated with the OncoPrinter and MutationMapper tools available at cBioPortal (32, 33) . Mutations were evaluated across samples using InVEx algorithms to distinguish genes that appear targeted by driver rather than passenger mutations (34) .
Mutation point validation
To validate somatic mutations founded by the multiplex PCR-based NGS, we performed the conventional Sanger sequencing, restriction fragment length polymorphism analysis and TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA The mutation sites in FAT1 were amplified using primers designed to create restriction sites specific for the variations at these positions by restriction fragment length polymorphism. For TaqMan allelic discrimination assay, PCRs were carried out in a 96-well GeneAmp PCR System 9700 (Applied Biosystems) with reagents and 10 ng genomic DNA. After PCR, the TaqMan assay plates were then transferred to the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) to read the fluorescence intensity. The allelic specific fluorescence data were analyzed using the SDS v1.1 software (Applied Biosystems) to determine the genotype.
Immunohistochemistry
FAT1 immunoreactivity was detected through immunohistochemistry analysis, following previously reported protocols (35) . The primary antibody was polyclonal rabbit antihuman FAT1 (1:100 dilution; SigmaAldrich, St Louis, MO). Pre-immune rabbit immunoglobulin G was the negative control. The immunoreactivity intensity was scored in following four categories: 0 (no staining), 1+ (weak staining), 2+ (moderate staining) and 3+ (strong staining). The immunoscore was obtained by multiplying the percentage of positively stained tumor cells (0-100%) and corresponding immunostaining intensity (0 to 3+) to obtain a value ranging from 0 to 300 (36) . The median immunoscore was set as a cut-off point for high or low expression in subsequent survival analyses.
Cell culture, reagents and phenotypic assays
Human tongue cancer cell line SAS was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) and cultured using Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS). SCC25, FaDu and HSC3 are from ATCC. OECM-1 was a generous gift from Dr C.-L.Meng (National Defense Medical Center, Taiwan) and cultured with RPMI (Invitrogen) with 10% FBS. OC4 cell line was homemade by Dr C.-C.Yang (Department of Dentistry, National Yang-Ming University), SCC25, FaDu, OC4 and HSC3 cells were cultured with Dulbecco's modified Eagle's medium/ F12 (Invitrogen) with 10% FBS. OC3 cell line was established from patient with OSCC as reported previously (37) and grew in a medium composed of Dulbecco's modified Eagle's medium containing 10% FBS and keratinocyte serum-free medium (Invitrogen) in a 1:2 ratio. NOK were established from oral mucosal epithelium and grown in keratinocyte serum-free medium with low Ca 2+ (0.1 mM). Human umbilical vein endothelial cells were a gift from Dr C.-P.Chen (Department of Medical Research, MacKay Memorial Hospital). These cells were cultured in accordance with a previously established protocol (38) . These cell lines were authenticated by Mission Biotech (Nangang, Taipei, Taiwan) on 8 August 2017. The test was performed by using the Promega StemElite™ ID System and analyzed by an ABI PRISM 3730 Genetic Analyzer and GeneMapper® Software v3.7. The si-FAT1 and scramble control oligonucleotides were purchased from Santa Cruz Biotech (Santa Cruz, CA). TransFectin Lipid Reagent (Bio-Rad, Hercules, CA) was used as the transfection reagent. sh-FAT1 vectors (TRCN0000245156, TRCN0000245157 and TRCN0000245159) and an sh-Luc control vector (TRCN0000072249) packed in lentiviruses were purchased from National RNAi Core (Academia Sinica, Taipei, Taiwan). The cells were infected and selected using 5 μg/ml puromycin (Sigma-Aldrich) for 7 days to establish stable subclones. Phenotypic events, including proliferation, migration, invasion and transendothelial migration, was analyzed in accordance with previously published protocols (5,39).
Analysis of FAT1 mutations in HNSCC cell lines
Long-PCR amplicons were used to amplify all coding exons (exons 2-27) of FAT1 in OECM1, OC3, OC4, and HSC3 cells. The amplicons were sequenced with the ABI BigDye Terminator Cycle Sequencing Kit on an ABI 3730xl DNA Analyzer (Applied Biosystems). The variants with MAF > 1% in the 1000 Genomes Project and dbSNP137 were filtered.
Constructs
An enhanced green fluorescent protein (EGFP) coding sequence was amplified from pAS2.EGFP.puro (National RNAi Core) through PCR by using the primers EGFP_Forward and EGFP_Reverse containing a HindIII site. First, the complementary DNA (cDNA) fragment was cloned into the pcDNA6-myc-His vector (Invitrogen) to generate an EGFP-myc-His vector. The FAT1 cDNA sequence encoding amino acid residues from 3438 to 4588 was amplified from the cDNA of OC4 cells by using the primers FAT1_Forward and FAT1_Reverse containing HindIII and NotI sites. The PCR product was subcloned into the EGFP-myc-His vector, and this construct was named FAT1-Domains. The Q3461*, Q3872*, Q4088*, S3554A, C4076W and S4367S mutations were introduced into FAT1-Domains with the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA) by using the primers Q3461*mut, Q3872*mut, Q4088*mut, S3554Amut, C4076Wmut and S4367Smut, respectively. The constructed mutants were designated 3461-stop, 3872-stop, 4088-stop, p.S3554A, p.C4076W and p.S4367S, respectively. The oligonucleotide primers used in this section are listed in Supplementary Table 3 , available at Carcinogenesis Online.
Quantitative reverse transcription PCR
TRIzol reagent (Invitrogen) was used to isolate the total RNA, which was subsequently reverse transcribed into cDNA. TaqMan gene expression assays (Applied Biosystems) were performed to quantify the messenger RNA (mRNA) expression of FAT1 and GAPDH following the manufacturer's instructions. GAPDH served as the internal control for mRNA expression. The threshold cycle (C t ) method was used to measure relative changes in expression. Data were analyzed using the −ΔΔC t method, and the FAT1 mRNA abundance was calculated relative to the standard internal controls.
Western blotting
Western blotting was performed, as described previously (35 
OC4 cell xenografts
BALB/c nude mice (female, 6-week-old) were purchased from BioLASCO technology (Charles River, Taipei, Taiwan). OC4 (2 × 10 6 ) cells were injected subcutaneously into the flank of mice. Tumor volumes were calculated using the formula: volume = 0.5 × a × b 2 , where a and b were the long and short diameters of the tumors, respectively. Tumor diameters were measured using digital electronic caliper.
Statistical analysis
Data are presented as the mean ± standard error of mean. Chi-squared test and t-test as well as Spearman's correlation analysis were used. Overall survival (OS) was defined as the time between the first day of diagnosis and death, or the last date of follow-up. Disease-free survival (DFS) was defined as the time from the first day of diagnosis to the first recurrence. Patients without evidence of disease recurrence were censored at the last follow-up or death. Kaplan-Meier analysis was used to compare the OS and DFS between the two groups. The association between FAT1 mutations or immune scores and DFS was assessed using the multivariate Cox proportional hazards model. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were considered statistically significant. Cross-comparisons showing no statistically significant differences were not marked.
Results
Distribution of mutations in HNSCC
To identify protein-altering somatic mutations in HNSCC, five HNSCCs and matched normal samples were subjected to WES, yielding 3309 SNVs and 40 indels. After the elimination of variants with MAF > 1% in the 1000 Genomes Project and dbSNP137, 436 for SNVs and 28 for indels were retained for analysis. We further filtered variants that had predicted deleterious missense, nonsense and frameshift mutations, which resulted in 126 SNVs and 17 indels. Subsequently, we visually confirmed 61 SNVs and 5 indels in 64 genes by IGV (Supplementary Figure 3 and Table 5 , available at Carcinogenesis Online). We observed 11.8 ± 4.4 mutations in HNSCCs (summary in Supplementary Figure 1 , available at Carcinogenesis Online). TP53 and FAT1 deleterious mutations were identified in two patients, consistent with a previous study that TP53 and FAT1 are commonly mutated in HNSCC (13) . We further investigated the clinical and functional implications of FAT1 aberrances in HNSCC.
Somatic mutations in FAT1
Aberrant FAT1 expression has been reported to be involved in the pathogenesis of several cancers, including HNSCC (40) (41) (42) . However, the pathogenic implications of FAT1 alterations in HNSCC are yet to be established. To evaluate the performance of FAT1 in clinical assessments, 96 HNSCC samples were analyzed through multiplex PCR-based NGS. NGS identified 48 somatic mutations in these samples; of these mutations, 6 were synonymous, 13 were missense, 15 were nonsense and 14 were frameshift mutations (Figure 1A and B; Supplementary Figure 2C ). Furthermore, FAT1 mutations were significantly associated with positive lymphovascular permeation (P < 0.001) and tumor recurrence (P = 0.031). Table 7 , available at Carcinogenesis Online). Kaplan-Meier analysis indicated that patients with HNSCC harboring FAT1 mutations had significantly poorer DFS than did those with wild-type FAT1 (P = 0.007); however, no significant differences were observed in OS ( Figure 2G and H). Both univariate and adjusted multivariate Cox regression analyses revealed poorer DFS in patients with FAT1 mutations [hazard ratio (HR) = 3.88, P = 0.013; HR = 3.53, P = 0.028, respectively; Table I ].
FAT1 expression in patients with HNSCC
The FAT1 protein was detected in the cytosol and membrane of basal and parabasal cells in normal oral epithelium adjacent to tumors and human skin ( Figure 3A, top left) . FAT1 immunoreactivity in tumor tissues varied from faint and scattered ( Figure 3A , bottom left) to intense and diffuse ( Figure 3A , bottom right) reactivity. No staining was observed in negative control slide ( Figure 3A , top middle). The FAT1 immune score correlated negatively with FAT1 deleterious mutations (r = −0.445, P < 0.001; Figure 3B ). The lower immune score of FAT1 correlated significantly with lymph node metastasis (P = 0.009), lymphovascular permeation (P = 0.037) and tumor recurrence (P = 0.005; Figure 3C -H and Supplementary (P = 0.002). However, no significant differences were observed in OS ( Figure 3I and J). Both univariate and adjusted multivariate Cox regression analyses revealed shorter DFS in patients with lower FAT1 expression (HR = 6.31, P = 0.008; HR = 7.53, P = 0.027, respectively; Table I ).
Association between FAT1 repression and increased HNSCC invasion
Quantitative reverse transcription-PCR and western blotting were performed to measure the mRNA and protein levels of FAT1 in NOK and HNSCC cells. As shown in Figure 4A and B, six of the seven (85.7%) tested HNSCC cell lines exhibited decreased or no mRNA and protein expression of FAT1 relative to NOK cell lines. Only the OC4 cell line had higher endogenous FAT1 expression relative to the NOK cell line. The mRNA and protein expression of FAT1 in SAS and SCC25 cell lines was barely detectable ( Figure 4A and B). These findings are in agreement with previous studies reporting FAT1 deletion in these two cell lines (21, 41 Table 9 , available at Carcinogenesis Online). Each cell harbored 6.0 ± 1.8 damaging mutations. Three mutations were repeatedly detected in the different cell lines. OC4 cells carry the only a p.Asp1141Glu mutation, which is far fewer than the other three cell lines.
To investigate the oncogenic role of FAT1 in HNSCC, we established stable FAT1-knockdown OC4 and OECM1 subclones. The knockdown effect was confirmed through western blotting ( Figure 4C and G) . The knockdown of FAT1 expression did not change the proliferation ( Figure 4D and H) , but it significantly increased the migration and invasion of HNSCC cells ( Figure 4E , F, I and J). To confirm this result, OECM1 cells were transfected with si-FAT1 oligonucleotides ( Figure 4K ). The transient knockdown of FAT1 expression significantly increased the migration and invasion, but it did not change the proliferation of OECM1 cells ( Figure 4L-N) . These results indicate that FAT1 repression enhances the mobility and invasiveness of HNSCC cells. The knockdown of FAT1 expression also rendered the significant increase of the subcutaneous xenograft growth of OC4 in nude mice compared with control cells (Figure 4O 
Association between FAT1 mutations and increased HNSCC invasion
To elucidate the phenotypic effects of FAT1, a fragment of FAT1 spanning from the penultimate cadherin domain (codon 3438) to the ultimate codon (codon 4588), amplified from OC4 cells, was cloned to generate the FAT1-Domains construct. The fragment was sequenced to indicate a K4059N singlenucleotide polymorphism (rs1280097) and the absence of other nucleotide variations. This single-nucleotide polymorphism could have been eliminated in our mutational analysis. Three nonsense mutations, p.Gln3461Ter, p.Arg3872Ter and p.Gln4088Ter being found in tumor tissues (Supplementary Table 6 , available at Carcinogenesis Online), which were localized in the cadherin, lamin G-like and EGF-like domains, respectively ( Figure 5A ), were confirmed by somatic mutations through Sanger sequencing, restriction fragment length polymorphism analysis and TaqMan allelic discrimination assay (Supplementary Figure 2B -G, available at Carcinogenesis Online). We further generated constructs harboring these mutations to express truncated proteins. SAS and OECM1 cells exhibiting the absence or rather low FAT1 expression were transfected with vectors. An anti-EGFP antibody was used to detect protein expression in SAS ( Figure 5B ) and OECM1 ( Figure 5C CI, confidence interval; HR, hazard ratio.
*P < 0.05; **P < 0.01.
Transfection with truncated mutant 4088-stop yielded no rescue effect. No differences were observed in the proliferation of the transfected cell lines ( Figure 5D and H). Two missense mutations, p.Thr3554Ala and p.Cys4076Trp, localized in the cadherin domain and EGF-like domains, respectively, were found in HNSCC tumor tissues or cell lines (Supplementary Tables 6 and 9 , available at Carcinogenesis Online). We generated constructs harboring these base changes to express mutant FAT1-Domains. In addition, a construct containing synonymous p.Ser4367Ser mutation (Supplementary Table 9 , available at Carcinogenesis Online) was also generated to serve as a negative control. Transfection with FAT1-Domains vector and the mutant constructs yielded a 156 kDa band in SAS and OECM1 cells (Supplementary Figure 6A 
Discussion
Large-scale exome-sequencing studies have revealed different rates of FAT1 mutations in a wide range of HNSCCs and cell lines (13, 17, (43) (44) (45) . In TCGA cohort, non-synonymous somatic FAT1 mutations were identified in 26.9% of human papillomavirus-negative HNSCC and 24.2% of all HNSCCs (46) . FAT1 seems to be the second most mutated gene in HNSCC, only after TP53 (44) (45) (46) . However, these mutations documented in TCGA database have not been validated to date. This study is the first to verify somatic mutations in FAT1 in HNSCC through multiplex PCR-based NGS. Furthermore, all mutations were reconfirmed using IGV. A total of 29.2% HNSCCs in our cohort harbored deleterious FAT1 mutations, which is relatively similar to the findings in TCGA database. Nonsense mutations accounted for most (60.6%; 37/61) FAT1 loss-of-function mutations in HNSCC in TCGA cohort (46) . Each missense, nonsense and frameshift mutation accounted for approximately onethird of non-synonymous mutations in our samples. A literature review revealed very frequent FAT1 missense mutations (75.0%; 9/12) in HNSCC cell lines. In addition, SCC9, SCC25 and SAS cell lines harbored FAT1 deletion (43, 44) . Our preliminary assays revealed a high abundance of FAT1 missense mutations in HNSCC cell lines, which were not characterized previously. Missense mutations seem to be the major type of FAT1 mutation in HNSCC cell lines.
Sanger sequencing confirmed three specific nonsense mutations in the cadherin, lamin G-like and EGF-like domains; this confirmation of somatic FAT1 mutations has yet to be reported in HNSCC. Thus, despite FAT1 being a large gene encoding a protein of approximately 500 kDa, this NGS-based strategy facilitates a reliable platform for screening FAT1. No hotspot mutation has been reported previously or was observed in our study (13, 45) ; therefore, the allele-specific approaches targeting only common mutations (21, 22) are infeasible for exploring FAT1 mutations in HNSCC. The multiplex PCR assay was designed to generate FAT1 amplicon libraries for sequencing, which cover proteincoding regions and conserved splice sites. This approach may offer advantages over Sanger sequencing because of its potent scalability and less labor intensity. The strategies developed in this study facilitate investigating somatic mutations in FAT1 for individualized diagnosis.
In cancer, FAT1 can act as an oncogene or a tumor suppressor gene in a context-dependent manner (47) . FAT1 is upregulated in leukemia, and the prognosis of precursor B-cell acute lymphoblastic leukemia in patients with FAT1 upregulation is poor (23) . FAT1 is frequently downregulated in invasive breast tumors (48) , and the loss of FAT1 expression is associated with cancer progression and aggressiveness as well as poor prognosis (49) . Reduced FAT1 expression at its normal membranous location may be a potential prognostic marker for cholangiocarcinoma (20) . The frequent loss of heterozygosity of FAT1 was described in astrocytic tumors (22) . Although the inhibition of FAT1 in the HSC2 OSCC cell line suppressed migration (41) , the loss of chromosomal 4q35 locus, which harbors FAT1, has been frequently identified in OSCC cells (21, 50) . Our functional analysis results indicate that the expression of an FAT1 fragment encompassing essential domains conspicuously suppressed the mobility and invasiveness of HNSCC cells. Notably, FAT1 nonsense mutations resulting in the loss of key domains abrogated such suppression. These clues substantiate the suppressor roles of FAT1 in HNSCC invasion. Typically, 4q chromosomal deletion and somatic mutations in FAT1 in addition to the methylation of the FAT1 promoter have been reported to result in FAT1 inactivation in HNSCC or OSCC cells (21, 50) . As p.S3554A and p.C4076W did not abrogate the FAT1-mediated suppression, it is postulated that the functions of remained intact Cad or EGF repeats may compensate these mismatched mutants. Alternatively, other unspecified molecular alterations are required to collaborate with these mutations in HNSCC oncogenesis.
The inactivation of FAT1 through mutations was reported to promote Wnt signaling and tumorigenesis (17) . An association between FAT1 downregulation and the disruption of β-catenin localization was shown in HSC2 cells (41) . However, our preliminary assays could not consistently specify β-catenin activation following FAT1 downregulation in HNSCC cells. The complicated signaling modulation mediated by FAT1 and the differential expression pattern of FAT1 in HNSCC carcinogenesis need stratification.
Because OC4 cells harbor p.Asp1141Glu missense mutation, increased migration mediated by the knockdown of endogenous FAT1 might not account for the wild-type FAT1 function. Therefore, we expressed a segment containing essential FAT1 domains to confirm the suppressive phenotypes. The p.Asp1141Glu mutation causing the loss of nearly all domains inactivated the suppression activity; other mutation assays suggested that the lamin G-like domain is essential for maintaining this activity. These data accord with the results of our clinical analysis, showing more aggressive behaviors and recurring potentials of tumors with FAT1 mutations. However, despite the p.Gln4088Ter mutation resulting in the loss of transmembranous and cytosolic regions, the remaining extracellular FAT1 portion still drives the suppression of cell mobility. The mechanisms through which the diverse FAT1 mutations, particularly missense mutations, confer the loss-of-function of FAT1 must be determined. Alternatively, the controllable expression of mutant constructs is required to more accurately ascertain their oncogenic influences.
Our analysis results show a reverse correlation between somatic FAT1 mutations and FAT1 downregulation in HNSCC, which agrees with the analysis of TCGA database (46) . Our test results further specify that FAT1 mutations and downregulation result in higher tumor progression and recurrence. Notably, FAT1 mutations in tumors were associated with higher OS in TCGA cohort (46) . Our assays showed no association between FAT1 mutation and OS. Nevertheless, FAT1 mutations and low FAT1 expression resulted in the worse DFS. Conspicuous differences were observed in the mutation profiles reported in TCGA database and our cohort; therefore, such differences may underlie the discrepancy. Although the disparities remain to be further resolved, these findings agree with those reported in other types of malignancies (17, 49, 51) .
In conclusion, HNSCC is highly heterogeneous at both the cellular and genetic levels. The findings of this study reveal that FAT1 suppresses HNSCC progression. Somatic mutations in FAT1 may underlie the downregulation of FAT1 expression. FAT1 mutations and expression determine HNSCC recurrence; therefore, the proposed gene analysis may facilitate the identification of FAT1 mutations as a diagnostic marker or therapeutic target in head and neck carcinoma. Supplementary Figures 1-3 
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